PATENT CLAIM ANALYSIS

Application Number: 16225469
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["435", "007920"]

Abstract:
Methods and reagents are disclosed for minimizing a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises pretreating both an antibody and a sample to be subjected to a non-agglutination immunoassay. In the method the antibody and the sample are combined with a pretreatment agent selected from the group consisting of hydroxyphenyl-substituted C1-C5 carboxylic acids and metallic salts thereof and halogen-substituted C1-C5 carboxylic acids and metallic salts thereof in an amount effective to enhance the accuracy of the non-agglutination immunoassay.

Claim (Index 12):
A method of determining immunosuppressant drug in a sample suspected of containing the immunosuppressant drug, the method comprising a non-agglutination immunoassay comprising:\n (a) providing in combination in a medium:\n (i) the sample, \n (ii) a releasing agent for releasing the immunosuppressant drug from endogenous binding substances, wherein the releasing agent is selected from the group consisting of one or more of a structural analog of the immunosuppressant drug and a hemolytic agent, \n (iii) an antibody reagent comprising an antibody for the immunosuppressant drug, \n (iv) a pretreatment agent selected from the group consisting of hydroxyphenyl-substituted C1-C5 carboxylic acids and metallic salts thereof and halogen-substituted C1-C5 carboxylic acids and metallic salts thereof in an amount effective to enhance the accuracy of the non-agglutination immunoassay; \n (b) incubating the medium under conditions for binding of the antibody for the immunosuppressant drug to the immunosuppressant drug suspected of being in the sample, wherein the incubation temperature is 5 degrees C. to 99 degrees C. and the time period for the incubation is 0.2 seconds to 24 hours, (c) examining the medium for the presence of a complex comprising the immunosuppressant drug and the antibody for the immunosuppressant drug, the presence and/or amount of the complex indicating the presence and/or amount of the immunosuppressant drug in the sample, wherein the immunosuppressant drug is selected from the group consisting of cyclosporine, everolimus, siroliumus and tacrolimus.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.78182
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13282957', '13026756', '13196831', '12491394', '12845265']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6181003270836084
- 35 USC 102 Novelty (BERT): 0.4833390266774187
- Combined Prediction Score: 0.6046241970429894
- Mean Citation Score: 239.56573000000003
- Max Citation Score: 242.02159
- Similarity Product: 198.3149173722392

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test